Patents Assigned to Tularik
  • Pyrimidine derivatives
    Publication number: 20010018436
    Abstract: Compounds and compositions are provided which are useful for the treatment of viral infections, particularly human Cytomegalovirus infection. The compounds include novel pyrimidine-based derivatives.
    Type: Application
    Filed: December 15, 2000
    Publication date: August 30, 2001
    Applicant: Tularik Inc.
    Inventors: Timothy D. Cushing, Heather L. Mellon, Juan C. Jaen, John A. Flygare, Shi-Chang Miao, Xiaoqi Chen, Jay P. Powers
  • Arylsulfonanilide phosphates
    Publication number: 20010018430
    Abstract: The invention provides compounds, compositions and methods relating to novel arylsulfonanilide derivatives and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer, psoriasis, vascular restenosis, infections, atherosclerosis and hypercholesterolemia, or as lead compounds for the development of such agents.
    Type: Application
    Filed: February 7, 2001
    Publication date: August 30, 2001
    Applicant: Tularik, Inc.
    Inventor: Jonathan B. Houze
  • Interleukin-1 receptor accessory proteins, nucleic acids and methods
    Patent number: 6280955
    Abstract: The invention provides methods and compositions relating to IL-1RAcP proteins that regulate cellular signal transduction and transcriptional activation, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IL-1RAcP encoding nucleic acids purified from human cells. The invention provides isolated IL-1RAcP hybridization probes and primers capable of specifically hybridizing with the disclosed IL-1RAcP genes, IL-1RAcP-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
    Type: Grant
    Filed: December 16, 1997
    Date of Patent: August 28, 2001
    Assignee: Tularik Inc.
    Inventor: Zhaodan Cao
  • IRAK3 polypeptides and methods
    Patent number: 6262228
    Abstract: The invention provides methods and compositions relating to a novel kinase, IRAK3. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IRAK3 encoding nucleic acids or purified from human cells. The invention provides isolated IRAK3 hybridization probes and primers capable of specifically hybridizing with the disclosed IRAK3 genes, IRAK3-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
    Type: Grant
    Filed: August 17, 1998
    Date of Patent: July 17, 2001
    Assignee: Tularik Inc.
    Inventor: Zhaodan Cao
  • UCP3 genes
    Patent number: 6248561
    Abstract: The invention provides methods and compositions relating to a novel family of UCP3 polypeptides and related nucleic acids involved in metabolic regulation. The polypeptides may be produced recombinantly from transformed host cells from the disclosed mUCP3 encoding nucleic acids or purified from mammalian cells. The invention provides isolated mUCP3 hybridization probes, knock-out/in constructs and primers capable of specifically hybridizing with the disclosed mUCP3 genes, mUCP3-specific binding agents such as specific antibodies, animals and cells modified with the subject mUCP3 nucleic acids, and methods of making and using the subject compositions in the biopharmaceutical industry.
    Type: Grant
    Filed: February 14, 2000
    Date of Patent: June 19, 2001
    Assignee: Tularik Inc.
    Inventors: Ning Zhang, M. Catherine Amaral, Jin-Long Chen
  • Regulators of apoptosis
    Patent number: 6242569
    Abstract: The invention provides methods and compositions relating to apopotosis regulating proteins, known as Casper proteins, and related nucleic acids. The proteins may be produced recombinantly from transformed host cells from the disclosed Casper encoding nucleic acid or purified from human cells. The invention provides specific hybridization probes and primers capable of specifically hybridizing with the disclosed Casper gene, Casper-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
    Type: Grant
    Filed: February 5, 1997
    Date of Patent: June 5, 2001
    Assignee: Tularik, Inc.
    Inventors: Hong-Bing Shu, David V. Goeddel
  • IKK-&agr; proteins, nucleic acids and methods
    Patent number: 6235513
    Abstract: The invention provides methods and compositions relating to an I&kgr;B kinase, IKK-&agr;, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IKK-&agr; encoding nucleic acids or purified from human cells. The invention provides isolated IKK-&agr; hybridization probes and primers capable of specifically hybridizing with the disclosed IKK-&agr; genes, IKK-&agr;-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
    Type: Grant
    Filed: February 13, 1998
    Date of Patent: May 22, 2001
    Assignee: Tularik Inc.
    Inventors: Mike Rothe, Zhaodan Cao, Catherine Régnier
  • IKK-&agr; proteins, nucleic acids and methods
    Patent number: 6235492
    Abstract: The invention provides methods and compositions relating to an I&kgr;B kinase, IKK-&agr;, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IKK-&agr; encoding nucleic acids or purified from human cells. The invention provides isolated IKK-&agr; hybridization probes and primers capable of specifically hybridizing with the disclosed IKK-&agr; genes, IKK-&agr;-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
    Type: Grant
    Filed: February 26, 1998
    Date of Patent: May 22, 2001
    Assignee: Tularik Inc.
    Inventors: Mike Rothe, Zhaodan Cao, Catherine Régnier
  • IKK-&agr; proteins, nucleic acids and methods
    Patent number: 6235512
    Abstract: The invention provides methods and compositions relating to an I&kgr;B kinase, IKK-&agr;, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IKK-&agr; encoding nucleic acids or purified from human cells. The invention provides isolated IKK-&agr; hybridization probes and primers capable of specifically hybridizing with the disclosed IKK-&agr; genes, IKK-&agr;-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
    Type: Grant
    Filed: July 10, 1997
    Date of Patent: May 22, 2001
    Assignee: Tularik Inc.
    Inventors: Mike Rothe, Zhaodan Cao, Catherine Régnier
  • Monitoring of gene expression by detecting hybridization to nucleic acid arrays using anti-heteronucleic acid antibodies
    Patent number: 6232068
    Abstract: The present invention relates to anti-heteronucleic acid antibodies and their uses for detection of RNA-DNA duplexes on arrays. The invention provides a method for detection of total cellular RNA hybridization on microarrays, thus obviating the need for isolation of the poly(A)+ fraction.
    Type: Grant
    Filed: January 22, 1999
    Date of Patent: May 15, 2001
    Assignees: Rosetta Inpharmatics, Inc., Tularik Inc.
    Inventors: Peter S. Linsley, Patrick Baeuerle
  • Arylsulfonanilide ureas
    Patent number: 6214880
    Abstract: The invention provides compounds, compositions and methods relating to novel arylsulfonanilide derivatives and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer, psoriasis, vascular restenosis, infections, atherosclerosis and hypercholesterolemia, or as lead compounds for the development of such agents.
    Type: Grant
    Filed: September 21, 1999
    Date of Patent: April 10, 2001
    Assignee: Tularik Inc.
    Inventor: Jonathan B. Houze
  • Arylsulfonanilide phosphates
    Patent number: 6211167
    Abstract: The invention provides compounds, compositions and methods relating to novel arylsulfonanilide derivatives and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer, psoriasis, vascular restenosis, infrections, atherosclerosis and hypercholesterolemia, or as lead compounds for the development of such agents.
    Type: Grant
    Filed: June 14, 2000
    Date of Patent: April 3, 2001
    Assignee: Tularik Inc.
    Inventor: Jonathan B. Houze
  • RIP: novel human protein involved in tumor necrosis factor signal transduction
    Patent number: 6211337
    Abstract: The invention relates to a human Receptor Interacting Protein (hRIP), nucleic acids which encode hRIP and methods of using the subject compositions; in particular, methods such as hRIP-based in vitro binding assays and phosphorylation assays for screening chemical libraries for lead compounds for pharmacological agents.
    Type: Grant
    Filed: August 11, 1998
    Date of Patent: April 3, 2001
    Assignee: Tularik Inc.
    Inventors: Vijay R. Baichwal, Jianing Huang, Hailing Hsu, David V. Goeddel
  • High-throughput screening assays for modulators of STAT4 and STAT6 activity
    Patent number: 6207391
    Abstract: This invention provides receptor peptides that have a high affinity for STAT4 and STAT6 polypeptides. Also provided are assays that are useful for identifying compounds that modulate the interaction between STAT4 and STAT6 polypeptides and their respective cellular promoters. The assays are amenable to high throughput screening.
    Type: Grant
    Filed: March 31, 1998
    Date of Patent: March 27, 2001
    Assignee: Tularik Inc.
    Inventors: Pengguang Wu, Judi McKinney
  • PPAR-&ggr; modulators
    Patent number: 6200995
    Abstract: Modulators of PPAR&ggr; activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.
    Type: Grant
    Filed: January 20, 1999
    Date of Patent: March 13, 2001
    Assignee: Tularik Inc.
    Inventors: Fabienne De la Brouse-Elwood, Jin-Long Chen, Timothy D. Cushing, John A. Flygare, Jonathan B. Houze, Juan C. Jaen, Lawrence R. McGee, Shi-Chang Miao, Steven Marc Rubenstein, Patrick C. Kearney
  • Pyrimidine derivatives
    Patent number: 6200977
    Abstract: Compounds and compositions are provided which are useful for the treatment of viral infections, particularly human Cytomegalovirus infection. The compounds include novel pyrimidine-based derivatives.
    Type: Grant
    Filed: February 12, 1999
    Date of Patent: March 13, 2001
    Assignee: Tularik Inc.
    Inventors: Timothy D. Cushing, Heather L. Mellon, Juan C. Jaen, John A. Flygare, Shi-Chang Miao, Xiaoqi Chen, Jay P. Powers
  • High-throughput screening assays for modulators of nucleic acid topoisomerases
    Patent number: 6197527
    Abstract: This invention provides novel assays for topoisomerase activity and for identifying topoisomerase inhibitors. The assays include both solid-phase and liquid-phase methods that are amenable to high throughput screening methods. The assays of the invention are readily adaptable to numerous types of topoisomerase, and are capable of identifying novel classes of topoisomerase activity modulators.
    Type: Grant
    Filed: July 13, 1999
    Date of Patent: March 6, 2001
    Assignee: Tularik Inc.
    Inventors: Anthony Simon Lynch, Binoj Joseph Matthew
  • Benzenesulfonamides and benzamides as therapeutic agents
    Patent number: 6191170
    Abstract: The invention provides compounds, compositions and methods relating to novel aromatic derivatives and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer, psoriasis, vascular restenosis, infections, atherosclerosis and hypercholesterolemia, or as lead compounds for the development of such agents.
    Type: Grant
    Filed: January 7, 1999
    Date of Patent: February 20, 2001
    Assignee: Tularik Inc.
    Inventor: Julio C. Medina
  • c-IAP1 and c-IAP2: inhibitors of apoptosis
    Patent number: 6187557
    Abstract: The invention provides methods and compositions relating to novel human cellular inhibitor of apoptosis proteins (c-IAP1/2) comprising a series of defined structural domain repeats and/or a RING finger domain; in particular, at least two of: a particular first domain repeat, a particular second domain repeat, and a particular third domain repeat, and/or a particular RING finger domain. The proteins provide a c-IAP specific function, with preferred proteins being capable of modulating the induction of apoptosis; for example, by binding a human tumor necrosis factor receptor associated factor (TRAF). The compositions include nucleic acids which encode the subject c-IAP and hybridization probes and primers capable of hybridizing with the disclosed c-IAP genes.
    Type: Grant
    Filed: December 8, 1995
    Date of Patent: February 13, 2001
    Assignee: Tularik Inc.
    Inventors: Mike Rothe, David V. Goeddel
  • High throughput in vitro screening assays for transcription modulators
    Patent number: 6183956
    Abstract: High-throughput in vitro assays are provided for identifying modulators of transcription activity and RNA expression. New assays, related compositions, apparatus and integrated systems are provided.
    Type: Grant
    Filed: March 31, 1998
    Date of Patent: February 6, 2001
    Assignee: Tularik, Incorporated
    Inventors: Mohanram Sivaraja, Berta Strulovici, Osvaldo A. Flores